CO6251319A2 - Analogos de heteroaril amidas como antagonistas receptores p2x7 - Google Patents

Analogos de heteroaril amidas como antagonistas receptores p2x7

Info

Publication number
CO6251319A2
CO6251319A2 CO09146587A CO09146587A CO6251319A2 CO 6251319 A2 CO6251319 A2 CO 6251319A2 CO 09146587 A CO09146587 A CO 09146587A CO 09146587 A CO09146587 A CO 09146587A CO 6251319 A2 CO6251319 A2 CO 6251319A2
Authority
CO
Colombia
Prior art keywords
alkyl
cycloalkyl
membered heterocycloalkyl
mono
membered
Prior art date
Application number
CO09146587A
Other languages
English (en)
Spanish (es)
Inventor
Rajagopal Bakthavatchalam
Scott Michael Capitosti
Jun Yuan
David C Ihle
David J Wustrow
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO6251319A2 publication Critical patent/CO6251319A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO09146587A 2007-08-10 2009-12-22 Analogos de heteroaril amidas como antagonistas receptores p2x7 CO6251319A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10

Publications (1)

Publication Number Publication Date
CO6251319A2 true CO6251319A2 (es) 2011-02-21

Family

ID=40351102

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09146587A CO6251319A2 (es) 2007-08-10 2009-12-22 Analogos de heteroaril amidas como antagonistas receptores p2x7

Country Status (14)

Country Link
EP (1) EP2185560A4 (enExample)
JP (2) JP2010535816A (enExample)
KR (1) KR20100066422A (enExample)
CN (1) CN101778850A (enExample)
AU (1) AU2008286946B2 (enExample)
BR (1) BRPI0812594A2 (enExample)
CA (1) CA2691512A1 (enExample)
CO (1) CO6251319A2 (enExample)
EA (1) EA020332B1 (enExample)
IL (1) IL202550A0 (enExample)
NZ (1) NZ582056A (enExample)
SG (1) SG183699A1 (enExample)
UA (1) UA99729C2 (enExample)
WO (1) WO2009023623A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2243772T1 (sl) * 2009-04-14 2012-05-31 Affectis Pharmaceuticals Ag Novi antagonisti p x r in njihova uporaba
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
SI2707101T1 (sl) 2011-05-12 2019-06-28 Proteostasis Therapeutics, Inc. Regulatorji proteostaze
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
EP2734526B1 (en) 2011-07-22 2016-04-06 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists
BR112014017735B1 (pt) * 2012-01-20 2022-06-28 Idorsia Pharmaceuticals Ltd Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
MX368044B (es) * 2012-12-12 2019-09-17 Idorsia Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x7.
ES2614495T3 (es) * 2012-12-18 2017-05-31 Actelion Pharmaceuticals Ltd. Derivados de indol carboxamida como antagonistas del receptor P2X7
JP6282016B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd P2x7受容体アンタゴニストとしての複素環アミド誘導体
CN104918946B (zh) * 2013-01-22 2017-03-29 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 P2x7調控劑
AU2014290598B2 (en) * 2013-07-17 2018-11-08 Foundation For Neglected Disease Research Azaindole compounds, synthesis thereof, and methods of using the same
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
WO2016053947A1 (en) 2014-09-29 2016-04-07 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
JP6673932B2 (ja) * 2014-12-15 2020-03-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung インドール及びアザインドール誘導体、並びに神経変性疾患におけるそれらの使用
JP6462493B2 (ja) 2015-05-29 2019-01-30 株式会社デンソー 進入判定装置、進入判定方法
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
WO2021064569A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
WO2022062991A1 (zh) * 2020-09-22 2022-03-31 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
DE2931323A1 (de) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh Neue n-aminoalkylindol-derivate und ihre salze
DE3131527A1 (de) * 1981-08-08 1983-02-24 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
TW229140B (enExample) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
ATE293599T1 (de) * 1997-12-24 2005-05-15 Aventis Pharma Gmbh Indolderivate als faktor xa inhibitoren
CA2368829A1 (en) * 1999-04-09 2000-10-19 Astrazeneca Ab Adamantane derivatives
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
AU2001277731A1 (en) * 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
WO2003016254A1 (en) * 2001-08-09 2003-02-27 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
SI1549638T1 (sl) * 2002-10-03 2008-02-29 Hoffmann La Roche Indol-3-karboksiamidi kot aktivatorji glukokinaze(gk)
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
EP1578418A2 (en) * 2002-12-20 2005-09-28 Bayer HealthCare AG Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
TW200700387A (en) * 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
US20070213359A1 (en) * 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
AU2007217474A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors

Also Published As

Publication number Publication date
KR20100066422A (ko) 2010-06-17
EA200971085A1 (ru) 2010-06-30
AU2008286946B2 (en) 2013-11-21
IL202550A0 (en) 2010-06-30
AU2008286946A1 (en) 2009-02-19
EP2185560A4 (en) 2011-10-05
JP2015110566A (ja) 2015-06-18
WO2009023623A1 (en) 2009-02-19
CN101778850A (zh) 2010-07-14
UA99729C2 (en) 2012-09-25
BRPI0812594A2 (pt) 2015-06-23
NZ582056A (en) 2012-08-31
EA020332B1 (ru) 2014-10-30
EP2185560A1 (en) 2010-05-19
JP2010535816A (ja) 2010-11-25
SG183699A1 (en) 2012-09-27
CA2691512A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CO6251319A2 (es) Analogos de heteroaril amidas como antagonistas receptores p2x7
CO6251318A2 (es) Compuestos heterociclicos de 5 miembros como antagonistas p2x7
CO6190582A2 (es) Derivados de heteroarilamida
CO6241110A2 (es) Analogos deamidas heteroarilicas como antagonistas del p2x7
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
EA201170096A1 (ru) Замещенные производные пиримидона
CU20110190A7 (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
AR104208A1 (es) Compuestos bicíclicos como inhibidores de autotaxina (atx)
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
BR112014026457A2 (pt) compostos de tetrazolinona e seu uso como pesticidas
CO6261379A2 (es) Compuestos de ciclopentandiona y derivados utiles como herbicidas
ES2601518T3 (es) Composiciones plaguicidas
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
CO6321230A2 (es) Compuesto espiro, una sal aceptable para uso farmaceutico y un solvato del mismo y composicion farmaceutica que lo contenga
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
CO6150167A2 (es) Analogos de 2-fenoxipirimidinona
CO6251352A2 (es) Derivados de ciclopentanodiona activos como herbicidas
AR093184A1 (es) Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden
AR066107A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen.
BR112017019439A2 (pt) inibidores kv1.3 e sua aplicação médica
CO6251235A2 (es) Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FC Application refused